Tan Yao, Lu Yijie, Chen Sheng, Zou Chang, Qin Bo
Shenzhen Aier Eye Hospital, Aier Eye Hospital, Jinan University, Shenzhen, China.
Shenzhen Eye Hospital, Shenzhen Key Laboratory of Ophthalmology, Affiliated Hospital of Jinan University, Shenzhen, China.
Front Oncol. 2023 May 31;13:1161759. doi: 10.3389/fonc.2023.1161759. eCollection 2023.
In recent years, new therapeutic options to overcome the mechanisms of tumor immune suppression be effective in the treatment of cutaneous melanoma. These approaches have also been applied in ocular melanoma. The aim of this study is to present the current status and research hotspots of immunotherapy for ocular melanoma from a bibliometric perspective and to explore the field of immunotherapy for malignant ocular melanoma research.
In this study, the Web of Science Core Collection database (WoSCC) and Pubmed were selected to search the literature related to immunotherapy of ocular melanoma. Using VOSviewer, CiteSpace, the R package "bibliometrix," and the bibliometric online platform through the construction and visualization of bibliometric networks, the country/region, institution, journal, author, and keywords were analyzed to predict the most recent trends in research pertaining to ocular melanoma and immunotherapy.
A total of 401 papers and 144 reviews related to immunotherapy of ocular melanoma were included. The United States is the main driver of research in the field, ranking first in terms of the number of publications, total citations, and H-index. The UNIVERSITY OF TEXAS SYSTEM is the most active institution, contributing the most papers. Jager, Martine is the most prolific author, and Carvajal, Richard is the most frequently cited author. CANCERS is the most published journal in the field and J CLIN ONCOL is the most cited journal. In addition to ocular melanoma and immunotherapy, the most popular keywords were "uveal melanoma" and "targeted therapy". According to keyword co-occurrence and burst analysis, uveal melanoma, immunotherapy, melanoma, metastases, bap1, tebentafusp, bioinformatics, conjunctival melanoma, immune checkpoint inhibitors, ipilimumab, pembrolizumab, and other research topics appear to be at the forefront of this field's research and have the potential to remain a hot research topic in the future.
This is the first bibliometric study in the last 30 years to comprehensively map the knowledge structure and trends in the field of research related to ocular melanoma and immunotherapy. The results comprehensively summarize and identify research frontiers for scholars studying immunotherapy associated with ocular melanoma.
近年来，克服肿瘤免疫抑制机制的新治疗选择在皮肤黑色素瘤治疗中取得了成效。这些方法也已应用于眼黑色素瘤。本研究旨在从文献计量学角度呈现眼黑色素瘤免疫治疗的现状和研究热点，并探索恶性眼黑色素瘤免疫治疗研究领域。
本研究选择Web of Science核心合集数据库（WoSCC）和Pubmed检索与眼黑色素瘤免疫治疗相关的文献。利用VOSviewer、CiteSpace、R包“bibliometrix”以及文献计量在线平台，通过构建和可视化文献计量网络，对国家/地区、机构、期刊、作者和关键词进行分析，以预测眼黑色素瘤和免疫治疗相关研究的最新趋势。
共纳入401篇与眼黑色素瘤免疫治疗相关的论文和144篇综述。美国是该领域研究的主要推动力量，在出版物数量、总被引频次和H指数方面均排名第一。德克萨斯大学系统是最活跃的机构，发表的论文最多。马丁·亚格是发文量最多的作者，理查德·卡瓦哈尔是被引频次最高的作者。《癌症》是该领域发表论文最多的期刊，《临床肿瘤学杂志》是被引频次最高的期刊。除眼黑色素瘤和免疫治疗外，最热门的关键词是“葡萄膜黑色素瘤”和“靶向治疗”。根据关键词共现和爆发分析，葡萄膜黑色素瘤、免疫治疗、黑色素瘤、转移、bap1、替贝福司、生物信息学、结膜黑色素瘤、免疫检查点抑制剂、伊匹木单抗、帕博利珠单抗等研究主题似乎处于该领域研究的前沿，未来有可能仍是热门研究课题。
这是过去30年中首次全面描绘眼黑色素瘤和免疫治疗相关研究领域知识结构和趋势的文献计量学研究。研究结果全面总结并确定了研究眼黑色素瘤相关免疫治疗的学者的研究前沿。
